EUVIMEDEUVIMED entdecken
Crossref

26-A-20358-ACC ATRIAL FIBRILLATION WITHOUT HEART FAILURE: CAN SGLT2 INHIBITORS IMPROVE PROGNOSIS?

Krutagni Adwait A. Mehta, Ritu C. Tated, Sameh Elias, Shruthi Badam, Rafey Feroze, Shilpkumar Arora

JACC · 2026-04 · 87 (13) · A134

DOI: 10.1016/j.jacc.2026.02.338 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JACC, 2026-04. Verfasst von Krutagni Adwait A. Mehta und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Mehta, K. A. A., Tated, R. C., Elias, S., Badam, S., Feroze, R., & Arora, S. (2026). 26-A-20358-ACC ATRIAL FIBRILLATION WITHOUT HEART FAILURE: CAN SGLT2 INHIBITORS IMPROVE PROGNOSIS?. JACC, 87(13), A134. https://doi.org/10.1016/j.jacc.2026.02.338

Vancouver

Mehta KAA, Tated RC, Elias S, Badam S, Feroze R, Arora S. 26-A-20358-ACC ATRIAL FIBRILLATION WITHOUT HEART FAILURE: CAN SGLT2 INHIBITORS IMPROVE PROGNOSIS?. JACC. 2026;87(13):A134. doi:10.1016/j.jacc.2026.02.338

BibTeX
@article{Mehta2026,
  author = {Mehta, Krutagni Adwait A. and Tated, Ritu C. and Elias, Sameh and Badam, Shruthi and Feroze, Rafey and Arora, Shilpkumar},
  title = {26-A-20358-ACC ATRIAL FIBRILLATION WITHOUT HEART FAILURE: CAN SGLT2 INHIBITORS IMPROVE PROGNOSIS?},
  journal = {JACC},
  year = {2026},
  volume = {87},
  number = {13},
  pages = {A134},
  doi = {10.1016/j.jacc.2026.02.338}
}
Kostenlos starten →